Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

BACKGROUND: An upgraded understanding of factors (sex/estrogen) associated with survival benefit in advanced colorectal carcinoma (CRC) could improve personalised management and provide innovative insights into anti-tumour mechanisms. The aim of this study was to assess the efficacy and safety of ce...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Huang, Chunlong, Gu, Xiaoyuan, Zeng, Xianshang, Chen, Baomin, Yu, Weiguang, Chen, Meiji
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7789412/
https://ncbi.nlm.nih.gov/pubmed/33413175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07770-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky